These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 28922577)

  • 1. Functional N-Formyl Peptide Receptor 2 (FPR2) Antagonists Based on the Ureidopropanamide Scaffold Have Potential To Protect Against Inflammation-Associated Oxidative Stress.
    Stama ML; Lacivita E; Kirpotina LN; Niso M; Perrone R; Schepetkin IA; Quinn MT; Leopoldo M
    ChemMedChem; 2017 Nov; 12(22):1839-1847. PubMed ID: 28922577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel ureidopropanamide based N-formyl peptide receptor 2 (FPR2) agonists with potential application for central nervous system disorders characterized by neuroinflammation.
    Stama ML; Ślusarczyk J; Lacivita E; Kirpotina LN; Schepetkin IA; Chamera K; Riganti C; Perrone R; Quinn MT; Basta-Kaim A; Leopoldo M
    Eur J Med Chem; 2017 Dec; 141():703-720. PubMed ID: 29102463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-peptide ligand binding to the formyl peptide receptor FPR2--A comparison to peptide ligand binding modes.
    Stepniewski TM; Filipek S
    Bioorg Med Chem; 2015 Jul; 23(14):4072-81. PubMed ID: 25882522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, Synthesis, Biological Evaluation, and Computational Studies of Novel Ureidopropanamides as Formyl Peptide Receptor 2 (FPR2) Agonists to Target the Resolution of Inflammation in Central Nervous System Disorders.
    Mastromarino M; Favia M; Schepetkin IA; Kirpotina LN; Trojan E; Niso M; Carrieri A; Leśkiewicz M; Regulska M; Darida M; Rossignolo F; Fontana S; Quinn MT; Basta-Kaim A; Leopoldo M; Lacivita E
    J Med Chem; 2022 Mar; 65(6):5004-5028. PubMed ID: 35257581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 3-(1H-indol-3-yl)-2-[3-(4-nitrophenyl)ureido]propanamide enantiomers with human formyl-peptide receptor agonist activity: molecular modeling of chiral recognition by FPR2.
    Schepetkin IA; Kirpotina LN; Khlebnikov AI; Leopoldo M; Lucente E; Lacivita E; De Giorgio P; Quinn MT
    Biochem Pharmacol; 2013 Feb; 85(3):404-16. PubMed ID: 23219934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FPR2-based anti-inflammatory and anti-lipogenesis activities of novel meroterpenoid dimers from Ganoderma.
    Peng XR; Wang Q; Wang HR; Hu K; Xiong WY; Qiu MH
    Bioorg Chem; 2021 Nov; 116():105338. PubMed ID: 34521045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent advances in the design and development of formyl peptide receptor 2 (FPR2/ALX) agonists as pro-resolving agents with diverse therapeutic potential.
    Maciuszek M; Cacace A; Brennan E; Godson C; Chapman TM
    Eur J Med Chem; 2021 Mar; 213():113167. PubMed ID: 33486199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The proteolytically stable peptidomimetic Pam-(Lys-βNSpe)6-NH2 selectively inhibits human neutrophil activation via formyl peptide receptor 2.
    Skovbakke SL; Heegaard PM; Larsen CJ; Franzyk H; Forsman H; Dahlgren C
    Biochem Pharmacol; 2015 Jan; 93(2):182-95. PubMed ID: 25462815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The leukocyte chemotactic receptor FPR2, but not the closely related FPR1, is sensitive to cell-penetrating pepducins with amino acid sequences descending from the third intracellular receptor loop.
    Forsman H; Bylund J; Oprea TI; Karlsson A; Boulay F; Rabiet MJ; Dahlgren C
    Biochim Biophys Acta; 2013 Aug; 1833(8):1914-23. PubMed ID: 23562731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microglia Depletion Attenuates the Pro-Resolving Activity of the Formyl Peptide Receptor 2 Agonist AMS21 Related to Inhibition of Inflammasome NLRP3 Signalling Pathway: A Study of Organotypic Hippocampal Cultures.
    Tylek K; Trojan E; Leśkiewicz M; Ghafir El Idrissi I; Lacivita E; Leopoldo M; Basta-Kaim A
    Cells; 2023 Nov; 12(21):. PubMed ID: 37947648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gastrin-releasing peptide/neuromedin B receptor antagonists PD176252, PD168368, and related analogs are potent agonists of human formyl-peptide receptors.
    Schepetkin IA; Kirpotina LN; Khlebnikov AI; Jutila MA; Quinn MT
    Mol Pharmacol; 2011 Jan; 79(1):77-90. PubMed ID: 20943772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mitocryptide-2: Identification of Its Minimum Structure for Specific Activation of FPR2-Possible Receptor Switching from FPR2 to FPR1 by Its Physiological C-terminal Cleavages.
    Marutani T; Nishino K; Miyaji T; Kamada K; Ohura K; Kiso Y; Mukai H
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33920954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The non-steroidal anti-inflammatory drug piroxicam blocks ligand binding to the formyl peptide receptor but not the formyl peptide receptor like 1.
    Stenfeldt AL; Karlsson J; Wennerås C; Bylund J; Fu H; Dahlgren C
    Biochem Pharmacol; 2007 Oct; 74(7):1050-6. PubMed ID: 17692291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Annexin-1 signals mitogen-stimulated breast tumor cell proliferation by activation of the formyl peptide receptors (FPRs) 1 and 2.
    Khau T; Langenbach SY; Schuliga M; Harris T; Johnstone CN; Anderson RL; Stewart AG
    FASEB J; 2011 Feb; 25(2):483-96. PubMed ID: 20930115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renoprotective effect of isoliquiritigenin on cisplatin-induced acute kidney injury through inhibition of FPR2 in macrophage.
    Rui-Zhi T; Ke-Huan X; Yuan L; Xiao L; Bing-Wen Z; Tong-Tong L; Li W
    J Pharmacol Sci; 2022 Jan; 148(1):56-64. PubMed ID: 34924130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and evaluation of novel cyclopentane urea FPR2 agonists and their potential application in the treatment of cardiovascular inflammation.
    Maciuszek M; Ortega-Gomez A; Maas SL; Perretti M; Merritt A; Soehnlein O; Chapman TM
    Eur J Med Chem; 2021 Mar; 214():113194. PubMed ID: 33548634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural basis of ligand binding modes at the human formyl peptide receptor 2.
    Chen T; Xiong M; Zong X; Ge Y; Zhang H; Wang M; Won Han G; Yi C; Ma L; Ye RD; Xu Y; Zhao Q; Wu B
    Nat Commun; 2020 Mar; 11(1):1208. PubMed ID: 32139677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Asymmetric Synthesis and Biological Screening of Quinoxaline-Containing Synthetic Lipoxin A
    de Gaetano M; Tighe C; Gahan K; Zanetti A; Chen J; Newson J; Cacace A; Marai M; Gaffney A; Brennan E; Kantharidis P; Cooper ME; Leroy X; Perretti M; Gilroy D; Godson C; Guiry PJ
    J Med Chem; 2021 Jul; 64(13):9193-9216. PubMed ID: 34138563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FPR2 signaling without β-arrestin recruitment alters the functional repertoire of neutrophils.
    Gabl M; Holdfeldt A; Sundqvist M; Lomei J; Dahlgren C; Forsman H
    Biochem Pharmacol; 2017 Dec; 145():114-122. PubMed ID: 28855087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Airway lipoxin A4/formyl peptide receptor 2-lipoxin receptor levels in pediatric patients with severe asthma.
    Gagliardo R; Gras D; La Grutta S; Chanez P; Di Sano C; Albano GD; Vachier I; Montalbano AM; Anzalone G; Bonanno A; Riccobono L; Gjomarkaj M; Profita M
    J Allergy Clin Immunol; 2016 Jun; 137(6):1796-1806. PubMed ID: 26971688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.